NASDAQ:BSTC - BioSpecifics Technologies Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$43.00 +0.19 (+0.44 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$43.00
Today's Range$42.28 - $43.2341
52-Week Range$38.05 - $53.96
Volume15,498 shs
Average Volume14,939 shs
Market Capitalization$308.20 million
P/E Ratio25.29
Dividend YieldN/A
Beta1.46

About BioSpecifics Technologies (NASDAQ:BSTC)

BioSpecifics Technologies logoBioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brand names. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.

Receive BSTC News and Ratings via Email

Sign-up to receive the latest news and ratings for BSTC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:BSTC
CUSIP09093110
Phone516-593-7000

Debt

Debt-to-Equity RatioN/A
Current Ratio18.34
Quick Ratio18.34

Price-To-Earnings

Trailing P/E Ratio25.29
Forward P/E Ratio20.57
P/E GrowthN/A

Sales & Book Value

Annual Sales$27.44 million
Price / Sales11.28
Cash Flow$2.0476 per share
Price / Cash21.00
Book Value$11.37 per share
Price / Book3.78

Profitability

EPS (Most Recent Fiscal Year)$1.70
Net Income$11.32 million
Net Margins44.57%
Return on Equity18.92%
Return on Assets17.19%

Miscellaneous

Employees5
Outstanding Shares7,200,000

BioSpecifics Technologies (NASDAQ:BSTC) Frequently Asked Questions

What is BioSpecifics Technologies' stock symbol?

BioSpecifics Technologies trades on the NASDAQ under the ticker symbol "BSTC."

How were BioSpecifics Technologies' earnings last quarter?

BioSpecifics Technologies Co. (NASDAQ:BSTC) issued its quarterly earnings results on Wednesday, May, 9th. The biopharmaceutical company reported $0.54 EPS for the quarter, missing analysts' consensus estimates of $0.59 by $0.05. The biopharmaceutical company earned $7.09 million during the quarter, compared to analysts' expectations of $7.97 million. BioSpecifics Technologies had a net margin of 44.57% and a return on equity of 18.92%. View BioSpecifics Technologies' Earnings History.

When is BioSpecifics Technologies' next earnings date?

BioSpecifics Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for BioSpecifics Technologies.

What price target have analysts set for BSTC?

1 brokerages have issued 1-year target prices for BioSpecifics Technologies' stock. Their forecasts range from $65.00 to $65.00. On average, they anticipate BioSpecifics Technologies' stock price to reach $65.00 in the next year. View Analyst Ratings for BioSpecifics Technologies.

What are Wall Street analysts saying about BioSpecifics Technologies stock?

Here are some recent quotes from research analysts about BioSpecifics Technologies stock:
  • 1. According to Zacks Investment Research, "BIOSPECIFICS TECHNOLOGIES is engaged in the business of producing and licensing, for sale by other, a U.S. Food and Drug Administration (FDA) approved enzyme derived from collagenase, named Collagenase ABC, and researching, developing and clinically testing additional products derived therefrom for potential use as pharmaceuticals. " (3/16/2018)
  • 2. HC Wainwright analysts commented, "We have adjusted our revenue projection for BSTC accordingly, and our current 2017 revenue projection is $28.0M vs. the prior $29.6M, suggesting 7% YoY growth, while our 2018 revenue estimate is now $29.4M vs. the prior $32M." (8/10/2017)

Who are some of BioSpecifics Technologies' key competitors?

Who are BioSpecifics Technologies' key executives?

BioSpecifics Technologies' management team includes the folowing people:
  • Mr. Thomas L. Wegman, CEO, Pres, Principal Financial Officer, Principal Accounting Officer, Sec. & Director (Age 63)

Has BioSpecifics Technologies been receiving favorable news coverage?

Press coverage about BSTC stock has been trending somewhat positive this week, according to Accern Sentiment. The research firm rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. BioSpecifics Technologies earned a daily sentiment score of 0.16 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 45.66 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are BioSpecifics Technologies' major shareholders?

BioSpecifics Technologies' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.48%), Dimensional Fund Advisors LP (3.75%), Summit Trail Advisors LLC (3.25%), Elk Creek Partners LLC (2.29%), Eagle Asset Management Inc. (2.09%) and Prudential Financial Inc. (1.02%). Company insiders that own BioSpecifics Technologies stock include Thomas Wegman and Toby Wegman. View Institutional Ownership Trends for BioSpecifics Technologies.

Which major investors are selling BioSpecifics Technologies stock?

BSTC stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Elk Creek Partners LLC, GSA Capital Partners LLP, Prudential Financial Inc., Dimensional Fund Advisors LP, New York State Common Retirement Fund, Atlantic Trust Group LLC and UBS Group AG. View Insider Buying and Selling for BioSpecifics Technologies.

Which major investors are buying BioSpecifics Technologies stock?

BSTC stock was acquired by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Thomson Horstmann & Bryant Inc., Matarin Capital Management LLC, Eagle Asset Management Inc., Summit Global Investments, Millennium Management LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for BioSpecifics Technologies.

How do I buy shares of BioSpecifics Technologies?

Shares of BSTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioSpecifics Technologies' stock price today?

One share of BSTC stock can currently be purchased for approximately $43.00.

How big of a company is BioSpecifics Technologies?

BioSpecifics Technologies has a market capitalization of $308.20 million and generates $27.44 million in revenue each year. The biopharmaceutical company earns $11.32 million in net income (profit) each year or $1.70 on an earnings per share basis. BioSpecifics Technologies employs 5 workers across the globe.

How can I contact BioSpecifics Technologies?

BioSpecifics Technologies' mailing address is 35 Wilbur Street, Lynbrook NY, 11563. The biopharmaceutical company can be reached via phone at 516-593-7000 or via email at [email protected]


MarketBeat Community Rating for BioSpecifics Technologies (BSTC)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  143 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  221
MarketBeat's community ratings are surveys of what our community members think about BioSpecifics Technologies and other stocks. Vote "Outperform" if you believe BSTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSTC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BioSpecifics Technologies (NASDAQ:BSTC) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for BioSpecifics Technologies in the last 12 months. Their average twelve-month price target is $65.00, suggesting that the stock has a possible upside of 51.16%. The high price target for BSTC is $65.00 and the low price target for BSTC is $65.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $65.00$65.00$65.00$65.00
Price Target Upside: 51.16% upside49.70% upside50.01% upside48.98% upside

BioSpecifics Technologies (NASDAQ:BSTC) Consensus Price Target History

Price Target History for BioSpecifics Technologies (NASDAQ:BSTC)

BioSpecifics Technologies (NASDAQ:BSTC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2018HC WainwrightSet Price TargetBuy$65.00HighView Rating Details
8/10/2016Rodman & RenshawReiterated RatingBuy$60.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

BioSpecifics Technologies (NASDAQ:BSTC) Earnings History and Estimates Chart

Earnings by Quarter for BioSpecifics Technologies (NASDAQ:BSTC)

BioSpecifics Technologies (NASDAQ:BSTC) Earnings Estimates

Current Year EPS Consensus Estimate: $2.09 EPS
Next Year EPS Consensus Estimate: $2.13 EPS

BioSpecifics Technologies (NASDAQ BSTC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2018        
5/9/2018Q1 2018$0.59$0.54$7.97 million$7.09 millionViewN/AView Earnings Details
3/14/2018Q4 2017$0.39$0.51$6.83 million$6.70 millionViewN/AView Earnings Details
11/10/2017Q3 2017$0.36$0.37$6.59 million$6.52 millionViewN/AView Earnings Details
8/9/2017Q2 2017$0.39$0.36$6.95 million$6.54 millionViewN/AView Earnings Details
5/10/2017Q1 2017$0.40$0.46$6.81 million$7.69 millionViewN/AView Earnings Details
3/15/2017Q4 2016$0.38$0.40$6.76 million$6.62 millionViewN/AView Earnings Details
11/9/2016Q3 2016$0.41$0.42$6.95 million$6.88 millionViewListenView Earnings Details
8/9/2016Q216$0.35$0.35$6.25 million$6.20 millionViewN/AView Earnings Details
5/10/2016Q116$0.37$0.39$6.25 million$6.60 millionViewListenView Earnings Details
3/14/2016Q416$0.33$0.36$4.60 million$6.10 millionViewListenView Earnings Details
11/9/2015Q315$0.39$7.51 million$6.30 millionViewN/AView Earnings Details
8/10/2015Q215$0.44$0.24$2.60 million$4.70 millionViewListenView Earnings Details
5/11/2015Q414$0.32$2.30 million$5.60 millionViewN/AView Earnings Details
3/13/2015Q4 2014$0.27$4.65 millionViewN/AView Earnings Details
11/10/2014Q314$0.19$0.20$4.00 million$4.00 millionViewN/AView Earnings Details
8/11/2014Q214$0.12$0.08$2.91 million$2.70 millionViewN/AView Earnings Details
5/8/2014Q114$0.07$0.11$2.46 million$2.80 millionViewN/AView Earnings Details
3/6/2014$0.17$0.25$3.99 million$4.07 millionViewN/AView Earnings Details
11/12/2013Q3$0.04$0.17$2.15 million$3.15 millionViewListenView Earnings Details
8/8/2013Q2 2013$0.02$0.15$2.12 million$3.27 millionViewN/AView Earnings Details
5/10/2013Q1 2013$0.18$0.19$3.41 million$3.98 millionViewN/AView Earnings Details
3/12/2013Q4 2012$0.07$0.16ViewN/AView Earnings Details
11/8/2012Q3 2012$0.08$0.07ViewN/AView Earnings Details
8/9/2012Q2 2012$0.13$0.10ViewN/AView Earnings Details
5/10/2012Q1 2012$0.49$0.11ViewN/AView Earnings Details
3/9/2012Q4 2011$0.01ViewN/AView Earnings Details
11/8/2011Q3 2011$0.08$0.04ViewN/AView Earnings Details
8/9/2011Q2 2011$0.41$0.36ViewN/AView Earnings Details
5/10/2011Q1 2011($0.06)$0.02ViewN/AView Earnings Details
3/11/2011Q4 2010($0.04)($0.04)ViewN/AView Earnings Details
11/8/2010Q3 2010($0.09)($0.08)ViewN/AView Earnings Details
8/6/2010Q2 2010($0.11)($0.15)ViewN/AView Earnings Details
5/7/2010Q1 2010($0.04)ViewN/AView Earnings Details
3/10/2010Q4 2009($0.09)ViewN/AView Earnings Details
11/5/2009Q3 2009($0.06)ViewN/AView Earnings Details
8/13/2009Q2 2009($0.01)ViewN/AView Earnings Details
4/11/2009Q2 2009($0.16)ViewN/AView Earnings Details
3/31/2009Q4 2008$0.80ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

BioSpecifics Technologies (NASDAQ:BSTC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

BioSpecifics Technologies (NASDAQ BSTC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.54%
Institutional Ownership Percentage: 58.17%
Insider Trading History for BioSpecifics Technologies (NASDAQ:BSTC)
Institutional Ownership by Quarter for BioSpecifics Technologies (NASDAQ:BSTC)

BioSpecifics Technologies (NASDAQ BSTC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/29/2016Thomas WegmanInsiderSell20,000$48.16$963,200.00964,824View SEC Filing  
11/29/2016Toby WegmanDirectorSell10,000$48.08$480,800.00View SEC Filing  
9/15/2016Thomas WegmanInsiderSell3,100$41.21$127,751.00View SEC Filing  
9/13/2016Thomas WegmanInsiderSell3,605$37.55$135,367.75View SEC Filing  
9/2/2016Thomas WegmanInsiderSell9,201$37.53$345,313.53View SEC Filing  
8/30/2016Thomas WegmanInsiderSell4,299$37.54$161,384.46View SEC Filing  
8/24/2016Thomas WegmanPresidentSell4,173$38.08$158,907.84191,722View SEC Filing  
8/23/2016Thomas WegmanPresidentSell4,100$38.60$158,260.00191,722View SEC Filing  
5/18/2016Thomas WegmanMajor ShareholderSell50,000$33.01$1,650,500.00220,772View SEC Filing  
5/18/2016Toby WegmanDirectorSell25,000$33.01$825,250.00View SEC Filing  
11/30/2015Thomas WegmanCEOSell2,000$50.00$100,000.00120,822View SEC Filing  
11/23/2015Thomas WegmanCEOSell14,000$50.09$701,260.00122,822View SEC Filing  
11/18/2015Thomas WegmanCEOSell10,849$50.08$543,317.92136,822View SEC Filing  
11/16/2015Thomas WegmanCEOSell27,151$52.44$1,423,798.44147,671View SEC Filing  
7/20/2015Paul GitmanDirectorSell8,692$53.00$460,676.00View SEC Filing  
6/23/2015Paul GitmanDirectorSell36,308$51.78$1,880,028.24View SEC Filing  
5/29/2015Paul GitmanDirectorSell15,000$46.76$701,400.00View SEC Filing  
5/27/2015Paul GitmanDirectorSell24,000$42.00$1,008,000.00View SEC Filing  
1/23/2015Paul GitmanDirectorSell5,887$41.00$241,367.00View SEC Filing  
1/16/2015Paul GitmanDirectorSell4,113$41.00$168,633.00View SEC Filing  
11/24/2014Toby WegmanDirectorSell12,050$39.07$470,793.50View SEC Filing  
11/14/2014Michael SchamrothDirectorSell5,200$39.20$203,840.00View SEC Filing  
11/14/2014Thomas WegmanMajor ShareholderSell40,000$38.96$1,558,400.00View SEC Filing  
6/20/2014Jeffrey Kenneth VogelInsiderSell88,329$27.43$2,422,864.47View SEC Filing  
6/12/2014Paul GitmanDirectorSell10,000$28.00$280,000.00View SEC Filing  
6/4/2014Henry MorganDirectorSell17,940$27.00$484,380.00View SEC Filing  
6/2/2014Henry MorganDirectorSell2,060$27.01$55,640.60View SEC Filing  
5/29/2014Henry MorganDirectorSell20,000$27.03$540,600.00View SEC Filing  
5/19/2014Henry MorganDirectorSell20,000$25.84$516,800.0017,193View SEC Filing  
1/23/2014Paul GitmanDirectorSell10,000$25.00$250,000.0059,425View SEC Filing  
12/9/2013Paul GitmanDirectorSell15,000$23.00$345,000.00View SEC Filing  
11/11/2013Paul GitmanDirectorSell5,000$20.00$100,000.00View SEC Filing  
9/5/2013Henry MorganDirectorSell17,850$18.48$329,868.00View SEC Filing  
9/3/2013Henry MorganDirectorSell2,150$18.35$39,452.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BioSpecifics Technologies (NASDAQ BSTC) News Headlines

Source:
DateHeadline
BioSpecifics Technologies (BSTC) Upgraded by BidaskClub to SellBioSpecifics Technologies (BSTC) Upgraded by BidaskClub to Sell
www.americanbankingnews.com - May 18 at 5:13 PM
Analysts Anticipate BioSpecifics Technologies Co. (BSTC) to Post $0.49 EPSAnalysts Anticipate BioSpecifics Technologies Co. (BSTC) to Post $0.49 EPS
www.americanbankingnews.com - May 15 at 5:19 AM
BioSpecifics Technologies (BSTC) Releases  Earnings Results, Misses Expectations By $0.05 EPSBioSpecifics Technologies (BSTC) Releases Earnings Results, Misses Expectations By $0.05 EPS
www.americanbankingnews.com - May 10 at 9:53 PM
HC Wainwright Reiterates "$65.00" Price Target for BioSpecifics Technologies (BSTC)HC Wainwright Reiterates "$65.00" Price Target for BioSpecifics Technologies (BSTC)
www.americanbankingnews.com - May 10 at 7:51 PM
BioSpecifics: 1Q Earnings SnapshotBioSpecifics: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 8:50 AM
BioSpecifics Technologies Corp. Reports First Quarter 2018 Financial ResultsBioSpecifics Technologies Corp. Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 8:50 AM
BioSpecifics Technologies (BSTC) Downgraded to Sell at ValuEngineBioSpecifics Technologies (BSTC) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - May 3 at 10:05 PM
HC Wainwright Analysts Give BioSpecifics Technologies (BSTC) a $65.00 Price TargetHC Wainwright Analysts Give BioSpecifics Technologies (BSTC) a $65.00 Price Target
www.americanbankingnews.com - April 30 at 11:08 AM
 Brokerages Set $65.00 Price Target for BioSpecifics Technologies Co. (BSTC) Brokerages Set $65.00 Price Target for BioSpecifics Technologies Co. (BSTC)
www.americanbankingnews.com - April 30 at 1:30 AM
BioSpecifics Technologies (BSTC) Downgraded to Strong Sell at BidaskClubBioSpecifics Technologies (BSTC) Downgraded to Strong Sell at BidaskClub
www.americanbankingnews.com - April 19 at 11:11 AM
Zacks: BioSpecifics Technologies Corp. (BSTC) Receives Consensus Rating of "Strong Buy" from BrokeragesZacks: BioSpecifics Technologies Corp. (BSTC) Receives Consensus Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - April 15 at 5:31 PM
BidaskClub Downgrades BioSpecifics Technologies (BSTC) to SellBidaskClub Downgrades BioSpecifics Technologies (BSTC) to Sell
www.americanbankingnews.com - April 14 at 8:31 AM
Should BioSpecifics Technologies Corp’s (NASDAQ:BSTC) Recent Earnings Worry You?Should BioSpecifics Technologies Corp’s (NASDAQ:BSTC) Recent Earnings Worry You?
finance.yahoo.com - April 13 at 8:58 AM
HC Wainwright Reiterates $72.00 Price Target for BioSpecifics Technologies (BSTC)HC Wainwright Reiterates $72.00 Price Target for BioSpecifics Technologies (BSTC)
www.americanbankingnews.com - April 11 at 12:11 AM
BioSpecifics Technologies (BSTC) "Buy" Rating Reiterated at HC WainwrightBioSpecifics Technologies' (BSTC) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - March 31 at 2:06 PM
Analysts Expect BioSpecifics Technologies Corp. (BSTC) to Post $0.59 Earnings Per ShareAnalysts Expect BioSpecifics Technologies Corp. (BSTC) to Post $0.59 Earnings Per Share
www.americanbankingnews.com - March 30 at 5:28 AM
Blog Exposure - Vericel Announced Publication of Results from Phase-3 SUMMIT Extension StudyBlog Exposure - Vericel Announced Publication of Results from Phase-3 SUMMIT Extension Study
finance.yahoo.com - March 27 at 9:03 AM
Zacks: BioSpecifics Technologies Corp. (BSTC) Receives Consensus Recommendation of "Strong Buy" from AnalystsZacks: BioSpecifics Technologies Corp. (BSTC) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - March 26 at 5:41 AM
BioSpecifics Technologies (BSTC) Lifted to Sell at BidaskClubBioSpecifics Technologies (BSTC) Lifted to Sell at BidaskClub
www.americanbankingnews.com - March 24 at 10:59 AM
Madrigal Pharmaceuticals (MDGL) Soars: Stock Adds 6.5% in SessionMadrigal Pharmaceuticals (MDGL) Soars: Stock Adds 6.5% in Session
finance.yahoo.com - March 20 at 4:53 PM
Zacks: BioSpecifics Technologies Corp. (BSTC) Given $65.00 Consensus Price Target by AnalystsZacks: BioSpecifics Technologies Corp. (BSTC) Given $65.00 Consensus Price Target by Analysts
www.americanbankingnews.com - March 20 at 1:28 AM
BioSpecifics Technologies (BSTC) Lifted to Buy at Zacks Investment ResearchBioSpecifics Technologies (BSTC) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - March 16 at 7:12 PM
New Research: Key Drivers of Growth for CNB Financial, Akebia Therapeutics, Mesoblast, 21Vianet Group, Old Line Bancshares, and BioSpecifics Technologies — Factors of Influence, Major Initiatives and Sustained ProductionNew Research: Key Drivers of Growth for CNB Financial, Akebia Therapeutics, Mesoblast, 21Vianet Group, Old Line Bancshares, and BioSpecifics Technologies — Factors of Influence, Major Initiatives and Sustained Production
finance.yahoo.com - March 16 at 8:53 AM
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2017 Financial ResultsBioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2017 Financial Results
www.prnewswire.com - March 14 at 8:40 AM
HC Wainwright Reaffirms "Buy" Rating for BioSpecifics Technologies (BSTC)HC Wainwright Reaffirms "Buy" Rating for BioSpecifics Technologies (BSTC)
www.americanbankingnews.com - March 13 at 1:39 PM
BioSpecifics Technologies Corp. Announces Presentation of Interim Data from Phase 1 Study of CCH for the Treatment of Uterine Fibroids at 65th Annual Scientific Meeting of the Society for Reproductive InvestigationBioSpecifics Technologies Corp. Announces Presentation of Interim Data from Phase 1 Study of CCH for the Treatment of Uterine Fibroids at 65th Annual Scientific Meeting of the Society for Reproductive Investigation
www.prnewswire.com - March 12 at 4:48 PM
BioSpecifics Technologies Corp. (BSTC) is Stonepine Capital Management LLCs 2nd Largest PositionBioSpecifics Technologies Corp. (BSTC) is Stonepine Capital Management LLC's 2nd Largest Position
www.americanbankingnews.com - March 6 at 2:53 PM
Sierra Oncology (SRRA) vs. BioSpecifics Technologies (BSTC) Financial SurveySierra Oncology (SRRA) vs. BioSpecifics Technologies (BSTC) Financial Survey
www.americanbankingnews.com - March 5 at 11:12 PM
 BioSpecifics Technologies Corp. (BSTC) Receives Average Rating of "Strong Buy" from Brokerages BioSpecifics Technologies Corp. (BSTC) Receives Average Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - March 5 at 5:14 AM
BioSpecifics Technologies (BSTC) Cut to Hold at Zacks Investment ResearchBioSpecifics Technologies (BSTC) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - February 27 at 7:54 PM
Zacks: BioSpecifics Technologies Corp. (BSTC) Receives Average Recommendation of "Strong Buy" from BrokeragesZacks: BioSpecifics Technologies Corp. (BSTC) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - February 18 at 3:16 AM
Comparing BioSpecifics Technologies (BSTC) & Tyme Technologies (TYME)Comparing BioSpecifics Technologies (BSTC) & Tyme Technologies (TYME)
www.americanbankingnews.com - February 9 at 3:48 PM
Head to Head Survey: ADMA Biologics (ADMA) and BioSpecifics Technologies (BSTC)Head to Head Survey: ADMA Biologics (ADMA) and BioSpecifics Technologies (BSTC)
www.americanbankingnews.com - February 6 at 9:14 AM
Analysts Expect BioSpecifics Technologies Corp. (BSTC) to Announce $0.39 EPSAnalysts Expect BioSpecifics Technologies Corp. (BSTC) to Announce $0.39 EPS
www.americanbankingnews.com - February 3 at 1:12 AM
ImmunoGen (IMGN) Soars: Stock Adds 10.3% in SessionImmunoGen (IMGN) Soars: Stock Adds 10.3% in Session
finance.yahoo.com - February 1 at 9:41 AM
RedHill Biopharma (RDHL) in Focus: Stock Moves 10.2% HigherRedHill Biopharma (RDHL) in Focus: Stock Moves 10.2% Higher
finance.yahoo.com - January 30 at 10:12 AM
BioSpecifics Technologies Corp. to Present at the NobleCon14 ConferenceBioSpecifics Technologies Corp. to Present at the NobleCon14 Conference
finance.yahoo.com - January 22 at 12:25 PM
BioSpecifics Technologies (BSTC) Lifted to Strong-Buy at Zacks Investment ResearchBioSpecifics Technologies (BSTC) Lifted to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - January 15 at 8:56 PM
Zacks: BioSpecifics Technologies Corp (BSTC) Receives Average Rating of "Strong Buy" from BrokeragesZacks: BioSpecifics Technologies Corp (BSTC) Receives Average Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - January 15 at 7:42 AM
BioSpecifics Technologies (BSTC) Lowered to Hold at Zacks Investment ResearchBioSpecifics Technologies (BSTC) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 12 at 5:54 PM
BioSpecifics Technologies (BSTC) and Its Peers Head to Head AnalysisBioSpecifics Technologies (BSTC) and Its Peers Head to Head Analysis
www.americanbankingnews.com - January 6 at 11:36 PM
BioSpecifics Technologies (BSTC) Stock Rating Reaffirmed by HC WainwrightBioSpecifics Technologies (BSTC) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - December 31 at 2:58 PM
BioSpecifics Technologies (BSTC) versus Its Competitors Critical AnalysisBioSpecifics Technologies (BSTC) versus Its Competitors Critical Analysis
www.americanbankingnews.com - December 31 at 9:30 AM
BioSpecifics Technologies (BSTC) & The Competition Head to Head ReviewBioSpecifics Technologies (BSTC) & The Competition Head to Head Review
www.americanbankingnews.com - December 31 at 5:30 AM
 BioSpecifics Technologies Corp (BSTC) Given $65.00 Average Target Price by Brokerages BioSpecifics Technologies Corp (BSTC) Given $65.00 Average Target Price by Brokerages
www.americanbankingnews.com - December 30 at 5:38 PM
ETFs with exposure to Biospecifics Technologies Corp. : December 29, 2017ETFs with exposure to Biospecifics Technologies Corp. : December 29, 2017
finance.yahoo.com - December 29 at 5:34 PM
BioSpecifics Technologies (BSTC) Upgraded to Hold by Zacks Investment ResearchBioSpecifics Technologies (BSTC) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - December 28 at 6:28 PM
Biospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : December 18, 2017Biospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : December 18, 2017
finance.yahoo.com - December 18 at 9:17 AM
Zacks: BioSpecifics Technologies Corp (BSTC) Given Consensus Rating of "Strong Buy" by AnalystsZacks: BioSpecifics Technologies Corp (BSTC) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - December 15 at 1:48 AM
ETFs with exposure to Biospecifics Technologies Corp. : December 13, 2017ETFs with exposure to Biospecifics Technologies Corp. : December 13, 2017
finance.yahoo.com - December 13 at 5:52 PM

SEC Filings

BioSpecifics Technologies (NASDAQ:BSTC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BioSpecifics Technologies (NASDAQ:BSTC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BioSpecifics Technologies (NASDAQ BSTC) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.